P P J Phillips
Overview
Explore the profile of P P J Phillips including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
224
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nash M, Deluca A, Lessem E, West N, McKenna L, McConnell E, et al.
IJTLD Open
. 2025 Jan;
2(1):56-58.
PMID: 39802229
No abstract available.
2.
Aggarwal I, Chaisson L, Opira B, Dowdy D, Phillips P, Semitala F, et al.
IJTLD Open
. 2024 Jul;
1(7):323-325.
PMID: 39035431
No abstract available.
3.
du Cros P, Greig J, Alffenaar J, Cross G, Cousins C, Berry C, et al.
Int J Tuberc Lung Dis
. 2023 Dec;
27(12):885-898.
PMID: 38042969
The value, speed of completion and robustness of the evidence generated by TB treatment trials could be improved by implementing standards for best practice. A global panel of experts participated...
4.
Chang V, Phillips P, Imperial M, Nahid P, Savic R
BMC Infect Dis
. 2022 Dec;
22(1):920.
PMID: 36494644
Background: Current tuberculosis (TB) regimen development pathways are slow and in urgent need of innovation. We investigated novel phase IIc and seamless phase II/III trials utilizing multi-arm multi-stage and Bayesian...
5.
Schwalb A, Cachay R, Wright A, Phillips P, Kaur P, Diacon A, et al.
Int J Tuberc Lung Dis
. 2022 Aug;
26(9):820-825.
PMID: 35996282
Multidrug-resistant TB (MDR-TB) clinical trial in Lima, Peru and Cape Town, South Africa. To identify baseline factors associated with screening failure and study withdrawal in an MDR-TB clinical trial. We...
6.
Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E, Bonnet M, et al.
Trials
. 2021 Sep;
22(1):651.
PMID: 34563240
Background: Treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR-TB) is expensive, labour-intensive, and associated with substantial adverse events and poor outcomes. While most MDR/RR-TB patients do not receive treatment, many who...
7.
Hills N, Lyimo J, Nahid P, Savic R, Lienhardt C, Phillips P
Trials
. 2021 Aug;
22(1):515.
PMID: 34344435
Background: Safe, more efficacious treatments are needed to address the considerable morbidity and mortality associated with pulmonary tuberculosis (TB). However, the current practice in TB therapeutics trials is to use...
8.
Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial
Phillips P, Van Deun A, Ahmed S, Goodall R, Meredith S, Conradie F, et al.
BMC Med
. 2020 Nov;
18(1):314.
PMID: 33143704
Background: The STREAM trial demonstrated that a 9-11-month "short" regimen had non-inferior efficacy and comparable safety to a 20+ month "long" regimen for the treatment of rifampicin-resistant tuberculosis. Imbalance in...
9.
Bogdanova E, Mariandyshev A, Balantcev G, Eliseev P, Nikishova E, Gaida A, et al.
PLoS One
. 2019 Jan;
14(1):e0211203.
PMID: 30695043
Background: The development of new diagnostic tools allows for faster detection of both tuberculosis (TB) and multidrug-resistant (MDR) TB and should lead to reduced transmission by earlier initiation of anti...
10.
Murthy S, Chatterjee F, CROOK A, Dawson R, Mendel C, Murphy M, et al.
BMC Med
. 2018 May;
16(1):73.
PMID: 29779492
Background: Chest radiographs are used for diagnosis and severity assessment in tuberculosis (TB). The extent of disease as determined by smear grade and cavitation as a binary measure can predict...